Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 6/20 | 0.49 |
| ▸ | AURKA | O14965 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 4/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CLK1 | P49759 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5032378 | 0.91 | KDR (0.48) | KDRAURKASMN1; SMN2AURKBRAB9A | |
| SCHEMBL5032432 | 0.91 | KDR (0.47) | KDRAURKASMN1; SMN2AURKBRAB9A | |
| SCHEMBL6426287 | 0.87 | KMT2A (0.45) | KDRAURKASMN1; SMN2AURKBRAB9A | |
| SCHEMBL6426072 | 0.87 | KMT2A (0.47) | KDRAURKASMN1; SMN2AURKBRAB9A | |
| SCHEMBL6427891 | 0.87 | MAPT (0.49) | KDRAURKASMN1; SMN2RAB9ANPC1 | |
| SCHEMBL5032428 | 0.85 | RAB9A (0.47) | AURKASMN1; SMN2RAB9ANPC1ALDH1A1 | |
| SCHEMBL5027599 | 0.84 | KDR (0.46) | KDRAURKASMN1; SMN2AURKBRAB9A | |
| SCHEMBL4144045 | 0.84 | KDR (0.67) | KDRAURKAAURKBFGFR1 | |
| SCHEMBL4144047 | 0.84 | KDR (0.67) | KDRAURKAAURKBFGFR1 | |
| SCHEMBL6427313 | 0.83 | KDR (0.45) | KDRAURKAAURKBRAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050261339-A1 | Pyrazole compound and medicinal composition containing the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261339-A1 | Pyrazole compound and medicinal composition containing the same | CNKSR1, NR3C2, CSNK2B | KDR 1044/4885AURKA 710/4885SMN1; SMN2 3772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.